DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Status
- TERMINATED
- Phase
- PHASE3
Different Immunosuppressive Treatment in iMN
- Status
- RECRUITING
- Phase
- PHASE3
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy
- Status
- UNKNOWN
- Phase
- N/A
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2